AZ drug for COPD fails first of two Phase 3 trials

AstraZeneca Plc’s antibody drug for chronic obstructive pulmonary disease (COPD), Fasenra (benralizumab), has failed to meet its primary endpoint in the first of two Phase 3 trials of patients with the disease.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom